Zobrazeno 1 - 10
of 19
pro vyhledávání: ''
Publikováno v:
Journal of Neuro-Oncology
PurposeEcotropic viral integration site-1 (EVI1) is a transcription factor that contributes to the unfavorable prognosis of leukemia, some epithelial cancers, and glial tumors. However, the biological function of EVI1 in glioblastoma multiforme (GBM)
Publikováno v:
Journal of Neuro-Oncology. 127:43-52
Ependymoma typically has a better overall survival rate than most gliomas. Only a few comprehensive clinical studies have been published, but these are mostly from Western countries and use small sample sizes. Histopathological classification is not
Publikováno v:
Journal of neuro-oncology. 139(1)
The efficacy of tyrosine kinase inhibitors (TKIs) with and without radiotherapy (RT) has not been determined in patients with brain metastases from epidermal growth factor receptor-mutant TKI naive non-small cell lung cancer (NSCLC). Between 2008 and
Autor:
Jian-ling Shi, Ming Yang, Huo-ming Chen, Mao-min Song, Suo-zhu Sun, Bo Li, Wei Xu, Xi-fan Wang
Publikováno v:
Journal of Neuro-Oncology. 124:79-85
To explore the correlation between epidermal growth factor receptor (EGFR) mutation status and the risk of brain metastasis (BM) in patients with lung adenocarcinoma, the clinical data of 100 patients with pathologically confirmed lung adenocarcinoma
Autor:
Xing Qiu, Kevin A. Walter, Dongmei Li, Rajiv Mangla, Wei Tian, Xiang Liu, Sven Ekholm, Mahlon D. Johnson
Publikováno v:
Journal of neuro-oncology. 135(3)
The radiogenomics association of neovascularization is important for overall survival (OS) in glioblastoma patients and remains unclear. The purpose of this study is to assess the association between MR perfusion imaging derived parameters and genomi
Autor:
Allan H. Friedman, Steven A. Thomas, Peter G. Kranz, Cory Adamson, Ranjith Babu, Vijay Agarwal, Roger E. McLendon, Darell D. Bigner
Publikováno v:
Journal of Neuro-Oncology. 119:177-185
Adult malignant brainstem gliomas (BSGs) are poorly characterized due to their relative rarity. We have examined histopathologically confirmed cases of adult malignant BSGs to better characterize the patient and tumor features and outcomes, including
Autor:
Peter Vajkoczy, Thorsten Pietsch, Felix Sahm, Michael Platten, Christian Hartmann, Joachim P. Steinbach, Alexander Radbruch, Manfred Jugold, Jonas Blaes, Stefan Pusch, Matthias Osswald, Michael Weller, Bettina Hentschel, Hanno Glimm, Markus Weiler, Manfred Westphal, Marcos Tatagiba, Gabriele Schackert, Carina M. Thome, Jörg C. Tonn, S. Luger, Wolfgang Wick, A. von Deimling, Matthias Simon, Frank Winkler, Dorothee Gramatzki, Marcus Czabanka, Maximilian G. Schliesser
Publikováno v:
Journal of Neuro-Oncology. 117:25-32
There is a lack of relevant prognostic and predictive factors in neurooncology besides mutation of isocitrate dehydrogenase 1, codeletion of 1p/19q and promoter hypermethylation of O 6 -methylguanine-DNA-methyltransferase. More importantly, there is
Autor:
Won Seok Chang, Byoung Chul Cho, Jin Woo Chang, Yong Gou Park, Hyun Ho Jung, Hye Ryun Kim, Young Cheol Na
Publikováno v:
Journal of neuro-oncology. 132(2)
The objective of this study was to elucidate the predictive factors for early distant brain failure in patients with brain metastases of non-small-cell lung cancer (NSCLC) who were treated with gamma knife radiosurgery (GKRS) without previous whole-b
Autor:
Wen Chang Huang, Ann-Lii Cheng, Jin-Yuan Shih, Ching-Hung Lin, Pei Fang Wu, James Chih-Hsin Yang, Yen-Shen Lu, Shang Gin Wu
Publikováno v:
Journal of Neuro-Oncology. 115:61-70
A greater understanding of brain metastases is imperative for developing novel therapeutic strategies. Our previous study showed that insulin-like growth factor (IGF) signaling pathway was activated in brain-tropic cancer cells. In this study, we inv
Autor:
John H. Sampson, Sridharan Gururangan, Allan H. Friedman, James E. Herndon, Henry S. Friedman, Annick Desjardins, Roger E. McLendon, J. Norfleet, Jennifer Marcello, David A. Reardon, James J. Vredenburgh
Publikováno v:
Journal of Neuro-Oncology. 96:219-230
We evaluated the anti-tumor activity and safety of erlotinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus sirolimus, an inhibitor of the mammalian target of rapamycin, among patients with recurrent glioblastoma